POMDOCTOR LTD - ADR
POMNASDAQTrading Snapshot
- Day Range
- $0.87 – $0.89
- 52-Week Range
- $0.50 – $115.74
- Volume
- $4.39B
- Avg Volume
- $4.78B
- Shares Outstanding
- 6.8M
- Next Earnings
- Nov 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $400M
- Last Q Revenue
- $103M
- P/E Ratio
- -1.6
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-3.66
- Dividend Yield
- 0.00%
Why Investors Own POM
- ✓High-growth profile — revenue up +43.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
POMDOCTOR LTD - ADR
POM
StockOtter · stockotter.spaceAbout POMDOCTOR LTD - ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model
GUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its di
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept.
POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy
GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the forma
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine
GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare
POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure
Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare c
POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities
GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare